Aug 3, 2026
HER2-Positive Breast Cancer: Targeted Therapies Explained
Understand the difference between FDA priority and standard ANDA reviews. Learn how GDUFA III timelines, first-generic exclusivity, and new domestic manufacturing pilots impact your approval speed and revenue.